<DOC>
	<DOCNO>NCT03087487</DOCNO>
	<brief_summary>The primary objective study compare risk major bleed stroke/systemic embolism ( SE ) event among oral anticoagulant ( OAC ) -na√Øve non-valvular atrial fibrillation ( NVAF ) patient initiate OAC warfarin apixaban treatment .</brief_summary>
	<brief_title>Clinical Economic Outcomes Oral Anticoagulants Non-valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Had 1 pharmacy claim apixaban warfarin identification period ( 01Jan2013 30Sep2015 ) . The first apixaban warfarin pharmacy claim date identification period designate index date 2 . Patients 18 year old old index date 3 . At least 1 diagnosis atrial fibrillation prior index date , identify medical claim 4 . At least 12 month baseline period prior index date continuous enrollment 1 . Evidence valvular heart disease , transient atrial fibrillation , venous thromboembolism 12month baseline period index date 2 . Evidence pregnancy study period 3 . Had pharmacy claim warfarin , apixaban , dabigatran , rivaroxaban , edoxaban 12month baseline period 4 . Had 1 oral anticoagulant claim index date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>